INTRODUCTION {#S1}
============

The induction of pluripotency in human somatic cells by defined transcription factors represents a breakthrough in regenerative medicine^[@R1]--[@R5]^. The generation of patient-specific human induced pluripotent stem cells (hiPSCs) and their autologous cell derivatives would help to overcome the problems of immune rejection and tissue availability. However, the applications of cell therapies in human patients are subject to very stringent safety requirements, and there is a general concern in the field about the safety of hiPSCs.

Successful generation of hiPSCs depends on the complete reprogramming of the somatic epigenome to a pluripotent state while the genome remains unchanged. Although initial reports demonstrated that human embryonic stem cells (hESCs) and hiPSCs were very similar, recent reports have uncovered striking genetic and epigenetic differences between these two pluripotent cell types^[@R6]--[@R11]^. It has been shown that hiPSCs display protein-coding mutations, large-scale genomic rearrangements, persistent epigenetic marks from the somatic cell type of origin and aberrant methylation patterns^[@R6],\ [@R9],\ [@R11]^. These findings indicated that hiPSCs contain genomic defects that could preclude their use in stem cell therapies. However, most of these studies focused on fibroblast-derived hiPSCs and a more comprehensive analysis is essential to determine whether there are specific somatic cell types that may reprogram into hiPSCs with fewer (or perhaps none) of these aberrations. Additionally, it is unclear whether the protein-coding mutations found in hiPSCs provide any functional advantage and thus, are selected for during the process of reprogramming.

In this work, we characterize at single nucleotide resolution the genomic integrity of eight hiPSC lines derived from five different non-fibroblast somatic cell types with varied reprogramming efficiencies. Moreover, we functionally characterize the role of 17 point mutations found in hiPSCs for their ability to increase reprogramming efficiency. We demonstrate that the majority of these mutations do not favor the reprogramming process and suggest that most of them originated randomly or were initially present in the somatic population of origin. Our observations of the genetic abnormalities of hiPSCs will contribute to a deeper understanding of the reprogramming process.

RESULTS {#S2}
=======

hiPSC lines from varied cell types contain protein-coding mutations {#S3}
-------------------------------------------------------------------

We previously sequenced the protein-coding regions of 22 fibroblast-derived hiPSC lines and discovered that the hiPSCs analyzed carried between 2 and 14 point mutations in protein-coding regions^[@R6]^. In this study, we sought to determine if low reprogramming efficiency (and therefore a potentially higher level of selection pressure which could allow the fixation of advantageous mutations) or cell type of origin (as fibroblasts could possess a higher somatic mutation rate than other cell types) could contribute to the overall reprogramming-associated mutational load. To this end, we performed targeted exome sequencing on eight non-fibroblast derived hiPSC lines and their five somatic cell types of origin using an in-solution hybridization capture method ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). Somatic mutations in each hiPSC line were identified via pairwise comparison with the matched somatic cell of origin and independently confirmed with capillary Sanger sequencing. We identified a total of 40 point mutations throughout all the hiPSC lines analyzed, leading to an average of 5 coding mutations per line ([Table 1](#T1){ref-type="table"}). As we identified \~89% of expected total single nucleotide polymorphisms at high sequencing depth in protein-coding regions, this led to a projection of 45 total mutations in protein-coding regions, or approximately 6 coding mutations per cell line. The levels of mutational load from each individual somatic cell type were statistically indistinguishable, and within the range previously observed for fibroblast-derived hiPSC lines^[@R6]^ ([Table 1](#T1){ref-type="table"}). These results indicate that hiPSC-associated mutations cannot be avoided by using younger or potentially more genetically protected somatic cell sources as progenitor cells. Moreover, we determined that reprogramming efficiency, which varies between 0.001--3% for these cell types, did not seem to have a measurable effect on the hiPSC mutational load. Thus, reprogramming-associated point mutations appear to be a general feature of hiPSCs.

We next investigated whether mutations in hiPSCs were either enriched or depleted in protein coding-regions. To this end, we examined additional non-coding regions captured in our sequencing analysis, and found a similar mutation rate per base pair analyzed for both coding and non-coding regions ([Table 2](#T2){ref-type="table"}). We also investigated whether point mutations in hiPSCs tended to occur in active/ubiquitous or silent/tissue-specific genes. Among a total of 132 mutated genes (from this study and Gore et al) annotated in the TiGER Database (TIssue-specific Gene Expression and Regulation)^[@R12]^, 37% of these genes showed tissue-specific expression, which is very similar to the overall level of tissue specificity observed in the genes annotated in the database (34%; p=0.4975), indicating that mutations are not preferentially occurring in silent genes. We additionally checked for any potential enrichment of mutations in active or inactive transcriptional regions of the genome^[@R13]^. We found that mutations were not significantly enriched in the active or inactive chromatin regions of fibroblasts (p-value=0.79), hESCs (p-value=0.29), or hiPSCs (p-value=0.07). Furthermore, only one gene (*NTRK3*) was found mutated in more than one independent hiPSC line and mutated genes did not cluster in a specific functional pathway (Gore et al^[@R6]^ and results herein). These combined findings suggest that mutations in hiPSCs are spread throughout both transcriptionally active and silent regions of the genome.

hiPSC-point mutations do not favor the process of reprogramming {#S4}
---------------------------------------------------------------

We previously showed that at least half of reprogramming-associated point mutations pre-exist in starting somatic cell populations at low frequency^[@R6]^. This leads to a hypothesis that a sub-population of somatic cells carrying certain mutations could be primed for reprogramming, which would be consistent with the elite model for reprogramming^[@R14]^. To investigate the functional potential of these mutations during reprogramming we first assessed whether mutated alleles were expressed in the hiPSC lines. We isolated RNA from 3 hiPSC lines, reverse-transcribed it into cDNA, and sequenced a total of 6 transcripts of randomly selected genes found mutated in these hiPSC lines. We detected heterozygous expression of both mutant and wild-type alleles in all cases ([Fig. 1](#F1){ref-type="fig"}) indicating that mutated transcripts are expressed in hiPSCs.

We next sought to determine if reprogramming-associated mutations could contribute functionally in facilitating the acquisition of pluripotency during reprogramming. From a total of 164 different genes found mutated in hiPSC lines (Gore et al^[@R6]^ and this study), we assayed the function of 17 candidate genes and their mutated forms during reprogramming ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}). These candidate genes were selected based on the likelihood of the mutation to change protein function, the mutation type (only nonsynonymous mutations were analyzed) and whether the gene was known to be related to the maintenance and/or acquisition of pluripotency^[@R6]^ ([Table 1](#T1){ref-type="table"}; [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}; [Supplementary Table S2](#SD1){ref-type="supplementary-material"}). We also analyzed the expression of these 17 genes in BJ fibroblasts, human umbilical vein endothelial cells (HUVEC), hESC and hiPSC lines to ensure gene expression in at least one of the somatic cell types used in this work ([Supplementary Fig. S2](#SD1){ref-type="supplementary-material"}). Due to the difficulty in predicting the functional consequences of each specific mutation, we first performed "loss-of-function" reprogramming experiments to mimic a possible diminished activity or protein instability of the mutated form. To this end, we designed a panel of lentiviruses encoding shRNAs against the selected genes ([Supplementary Fig. S3a](#SD1){ref-type="supplementary-material"}), and co-infected each separately with retroviruses expressing *OCT4*, *SOX2*, *KLF4* and *cMyc* (OSKC) in BJ fibroblasts ([Fig. 2a](#F2){ref-type="fig"}). Moreover, to determine whether these effects were cell-type specific we performed similar reprogramming experiments in HUVEC ([Supplementary Fig. S4a](#SD1){ref-type="supplementary-material"}). If a genetic mutation was selected for its ability to facilitate reprogramming due to a loss of protein function, it would be expected that down-regulation of the mutated gene would increase reprogramming efficiency. A decrease in reprogramming efficiency was detected after down-regulation of *FAIM3*, *SAMD3, ZNF16, MARCKSL1, NRP1, TRAF6, GSG1* and *HK1*, whereas no significant changes were detected after down-regulation of all but one of the assayed genes, POLR1C ([Fig. 2a](#F2){ref-type="fig"}, [Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}, [Supplementary Fig. S4b](#SD1){ref-type="supplementary-material"}). Interestingly, we observed that down-regulation of *POLR1C* in BJ fibroblasts, but not in HUVEC, resulted in an increased reprogramming efficiency. However, it is unclear if the specific reprogramming-associated mutation in POLR1C would result in the same phenotype. Overall, our data suggest that protein-coding point mutations generally do not prime rare cells for reprogramming through the loss-of-function mechanism.

Next, we performed "gain-of-function" reprogramming experiments to determine whether expression of the mutated form facilitated cell reprogramming. To this end, we designed a panel of retroviruses encoding both the wild type form and the corresponding mutated form found in hiPSCs of each specific gene (see specific mutations in [Supplementary Table S2](#SD1){ref-type="supplementary-material"}; [Supplementary Fig. S3b](#SD1){ref-type="supplementary-material"}), and co-expressed them with OSKC in BJ fibroblasts and HUVEC ([Fig. 2b](#F2){ref-type="fig"}, [Supplementary Fig. S4c](#SD1){ref-type="supplementary-material"}). If a mutation were selected during reprogramming due to a gain-of-function, it would be expected that expression of the mutated form would increase the reprogramming efficiency. We observed that only the expression of *HK1* slightly increased reprogramming efficiency ([Fig. 2b](#F2){ref-type="fig"} and [Supplementary Fig. S4c](#SD1){ref-type="supplementary-material"}). Importantly, we did not observe significant differences in reprogramming efficiency between cells over-expressing the mutated forms and cells over-expressing their respective wild-type forms ([Fig. 2b](#F2){ref-type="fig"}), indicating that the presence of the mutated protein does not increase reprogramming efficiency.

We have previously shown that both the mutant allele and the wild-type allele are expressed in hiPSCs ([Fig. 1](#F1){ref-type="fig"}). However, it is possible that a similar level of expression of the wild-type and mutant protein forms is necessary in order for the mutation to influence reprogramming efficiency in a gain-of-function manner. To clarify this, we performed a reprogramming experiment where OSKC were co-expressed together with a similar total amount of retrovirus encoding either only the wild type form or both the wild-type (wt) and mutant (mut) forms of a mutated gene in an equal ratio (1:1). Using this strategy, we were able to compare the reprogramming efficiency of cells over-expressing wild-type and mutated protein (wt/mut) in equal amounts with that of cells over-expressing wild-type protein alone (wt/wt). Interestingly, we did not observe any difference in reprogramming efficiency between cells over-expressing the wt/wt and wt/mut proteins ([Fig. 3a](#F3){ref-type="fig"}). Finally, we investigated whether silencing of retroviral transgenes during reprogramming could mask a gain-of-function effect of the mutated genes at a later stage of reprogramming. To this, we analyzed the reprogramming efficiency of cells infected with retroviruses expressing OSKC, the wild type or mutated forms of the genes evaluated in this study, and a red fluorescent protein (RFP) reporter gene to monitor transgene silencing. Reprogramming efficiency was evaluated based on the number of Tra-1-60^+^/RFP^+^ colonies present at day 14. These colonies represent putative bona-fide hiPSC colonies, as they express the stem cell marker Tra-1-60 but lack silencing of the exogenous transgenes. Thus, we only considered reprogramming events where transgene expression was still active. Importantly, we did not observe differences in reprogramming efficiency between cells over-expressing the mutated forms and cells over-expressing their respective wild-type forms ([Fig. 3b](#F3){ref-type="fig"}). Furthermore, we also evaluated reprogramming efficiency in the same experiment at day 14 by analyzing the number of Tra-1-60^+^/RFP^−^ colonies (evaluating putative bona-fide hiPSC colonies where transgene silencing occurred), and obtained a similar result (data not shown). Overall, these data suggest that most of these mutated genes do not facilitate reprogramming through a gain-of-function or loss-of-function mechanism.

DISCUSSION {#S5}
==========

Our work demonstrates that hiPSCs contain protein-coding mutations independent of the cell type of origin (as we analyzed hiPSC lines derived from five tissue types). Moreover, we determined that reprogramming efficiency, and therefore the level of selection pressure which could allow the fixation of advantageous mutations, did not to have a measurable effect on the hiPSC mutational load. Although the functional consequences of individual protein-coding mutations detected in hiPSCs remain to be characterized, these alterations could potentially contribute to the functional differences observed between hiPSC lines^[@R15]--[@R17]^. Two independent groups have recently reported the whole genome sequencing of human and murine iPSC lines and their corresponding somatic cell lines^[@R18]--[@R19]^. They identified hundreds of single nucleotide variants (SNVs) in non-coding regions as well as an average of 6--12 SNVs in coding regions^[@R18]--[@R19]^, which is consistent with our results^[@R6]^. Importantly, their data suggest that much of the genetic variation in iPSC clones pre-exists in the somatic population of origin and is fixed as a consequence of cloning individual cells during iPSC generation^[@R18]--[@R19]^. Although these reports supported previous observations^[@R6]^, they did not investigate whether identified mutations contribute functionally to facilitate the acquisition of pluripotency during reprogramming.

In this work, we show evidence suggesting that most reprogramming-associated point mutations do not provide a detectible selective advantage towards a reprogrammed state. Since inhibiting wild type POLR1C expression had a positive impact on reprogramming efficiency, we cannot rule out a potential role of the mutation found in POLR1C in facilitating reprogramming. If this is the case, the fact that down-regulation of POLR1C increases reprogramming efficiency in fibroblasts but not in HUVEC could indicate the existence of tissue-specific mutations affecting reprogramming efficiency, as PORL1C^P278R^ was found in one hiPSC line derived from human fibroblasts. Although it remains possible that untested mutated genes or a combination of mutations in a certain cellular context could play a role, the findings that only one gene (NTRK3) was found mutated in 2 out of 30 independent hiPSC lines, that mutated genes do not cluster in a specific functional pathway that could explain their selection during the reprogramming process, and that non-coding regions showed a similar mutational load, indicate that reprogramming-associated mutations seem to occur through a random process without selection and/or be initially present in the somatic population of origin^[@R18]--[@R19]^. It has been suggested that genomic alterations (i.e. duplications, deletions and mutations) are selected for during reprogramming, yet this has not been demonstrated^[@R6]--[@R11]^. In contrast to well-established recurrent genomic aberrations (e.g. chromosome 12 duplications) present in hESC or hiPSC lines that are functionally selected upon prolonged culture^[@R8]^, our results suggest that reprogramming-associated point mutations generally do not affect reprogramming efficiency although there could be exceptions. To our knowledge, the data provided herein provides for the first time a functional analysis of the role of specific genomic alterations (i.e. point mutations in coding regions) on the reprogramming process and have potential implications for the future of the hiPSC field in regenerative medicine.

METHODS {#S6}
=======

Cell culture {#S7}
------------

The hiPSC lines ASThiPS4F4, ASThiPS4F5, HUVhiPS4F1, HUVhiPS4F3, FhiPS4F7, NSChiPS2F and FhiPS3F1 were already described^[@R6],\ [@R20]--[@R22]^, and obtained from existing cultures. The hiPSC lines MSChiPS4F4, MSChiPS4F8 and KhiPS4F8 show all the requirements (morphology, pluripotent gene expression, normal karyotype and *in vivo* differentiation by teratoma formation) to define them as hiPSC cell lines. Derived hiPSCs were cultured as described^[@R24]^. 293T cells and BJ human fibroblasts (ATCC, CRL-2522) were cultured in DMEM (Invitrogen) supplemented with 10% FBS and 0.1 mM non-essential aminoacids. HUVEC cells were obtained from Lonza (C-2519A) and grown with EGM-2 media (Lonza) as recommended. MSCs were kindly provided by Cécile Volle (Sanofi-Aventis) and grown in α-MEM (Invitrogen) containing 10% FBS (Hyclone), penicillin/streptomycin, sodium pyruvate, nonessential amino acids, and L-glutamine (all from Invitrogen). Human keratinocytes were obtained and cultured as previously described^[@R23]^.

hiPSC generation {#S8}
----------------

To generate hiPSCs (KhiPS4F8, MSChiPS4F4 and MSChiPS4) or to evaluate reprogramming efficiency, experiments were performed as described with minor modifications^[@R24]^. Briefly, BJ fibroblasts, keratinocytes, MSCs or HUVEC cells were infected with an equal ratio of retroviruses or retroviruses plus lentiviruses by spinfection of the cells at 1850 rpm for 1 hour at room temperature in the presence of polybrene (4 μg/ml). After one (in case of the HUVEC cells), two (in case of the BJs fibroblasts or keratinocytes) or three (in case of the MSCs) viral infections viral infections, cells were trypsinized and transferred onto fresh irradiated mouse embryonic or human fibroblasts (iMEFs or iHFs) where correspond. One day after, cells were switched to hES cell medium (DMEM/F12 or KO-DMEM (Invitrogen) supplemented with 20% Knockout Serum Replacement (Invitrogen), 1 mM L-glutamine, 0.1 mM non-essential amino acids, 55 μM β-mercaptoethanol and 10 ng/ml bFGF (Joint Protein Central)). Depending on the cell type of origin, colonies were stained for Nanog expression at day 18 (in the case of HUVEC-derived hiPS cells) or 24 (in the case of BJ fibroblasts-derived hiPS cells) or isolated to establish cell lines. To calculate the efficiency of reprogramming, we plated the same number of infected HUVEC or BJ fibroblasts cells on iMEFs after the infection and the relative percentage of Nanog^+^ colonies to the value of the number of colonies generated with HUVEC or BJ fibroblasts cells infected with pLVTHM lentiviruses or GFP-expressing retroviruses correspondingly is shown.

Plasmid construction {#S9}
--------------------

The reprogramming plasmids pMX-*OCT4*, pMX-*SOX2*, pMX-*KLF4*, pMX-*cMyc* together with pLVTHM were obtained from Addgene (plasmids 17217, 17218, 17219, 17220 and 12247 respectively). For the construction of pMX-*NTRK3*, pMX-*FAIM3*, pMX-*POLR1C*, pMX-*GDF3* and pMX-*HK1* (fragment corresponding to the nucleotides 277-2753), specific coding region sequences were amplified by PCR from Human ORFeome library plasmids containing the corresponding cDNAs. cDNA fragments were digested with adequate restriction enzymes, purified and subcloned into linearized pMX plasmid. For the construction of pMX-*CCKBR*, pMX-*SAMD3*, pMX-*UBA2*, pMX-*TRAF6*, pMX-*MARCKSL1*, pMX-*CD1B*, pMX-*GSG1*, pMX-*NRP1*, pMX-*NEK11*, pMX-*CTSL1*, pMX-*ASB3* and pMX-*ZNF16*, specific pDONR223 plasmids from Human ORFeome library containing the corresponding cDNAs were used to transfer the cDNAs to the vector pMX-GW (Addgene, 18656). The transfer was achieved by using the Gateway LR Clonase enzyme mix (Invitrogen). The plasmids pMX-*p16*, pMX-*CDK4*, pMX-*CycD1*, pLVTHM-*CycE* and pLVTHM-*p53* were generated as described^[@R24],\ [@R25]^. The plasmid pMX-RFP was kindly provided by Dr. Guanghui Liu (Gene Expression Laboratory, The SALK Insitute, La Jolla, CA). For the introduction of specific point mutations in the coding sequences of the above genes (see [Supplementary Table S2](#SD1){ref-type="supplementary-material"} for specific mutations) the QuickChange Site-Directed Mutagenesis kit was used (Stratagene; see [Supplementary Table S3](#SD1){ref-type="supplementary-material"} for specific primers). For the generation of plasmids encoding shRNAs against the genes used in this study, specific oligos (see [Supplementary Table S3](#SD1){ref-type="supplementary-material"} for specific primers) were annealed, phosphorylated with T4 kinase and ligated into MluI/ClaI-linearized pLTVHM plasmid. The design of 3 different pairs of shRNAs was carried out using the SFold software (<http://sfold.wadsworth.org/>) and knockdown efficiency was assayed in 293T cells. The most efficient pairs of shRNAs were assayed in HUVEC or BJ fibroblasts cell ([Supplementary Fig. S1a](#SD1){ref-type="supplementary-material"}) and used in the corresponding experiments. All constructs generated were subjected to direct sequencing to rule out the presence of mutations.

Retroviral and lentiviral production {#S10}
------------------------------------

Moloney-based retroviral vectors (pMX and derived) and second generation lentiviral vectors (pLVTHM and derived) were co-transfected with packaging plasmids to generate viral particles in 293T cells using Lipofectamine (Invitrogen) as previously described^[@R24]^.

Immunostaining {#S11}
--------------

Imnunofluorescence analysis for the detection of pluripotent markers in hiPSCs or for the detection of differentiation-associated markers in teratomas were performed as described^[@R22]^. Immunohistochemical/immunoflorescence detection of Nanog or Tra-1-60 was performed as described^[@R24]^.

RNA isolation and real time-PCR analysis {#S12}
----------------------------------------

Total RNA was isolated using Trizol Reagent (Invitrogen) according to the manufacturer's recommendations. cDNA was synthesized using the SuperScript II Reverse Transcriptase kit for RT-PCR (Invitrogen) or the RT Supermix M-MuLV kit (BioPioneer). Real-time PCR was performed using the SYBR-Green PCR Master mix (Applied Biosystems) in the ViiA 7 Real Time PCR System (Applied Biosystems). GAPDH expression was used to normalize values of gene expression and data is shown as fold change relative to the value of the sample control. All the samples were done in triplicate. Primers used for real time-PCR experiments are listed in [Supplementary Table S3](#SD1){ref-type="supplementary-material"}.

Whole genome library construction {#S13}
---------------------------------

Library construction was performed as previously described^[@R6],\ [@R26]^. Briefly, for each sample, roughly 1.5 to 3 μg of genomic DNA (in 100 μl volumes) was sheared with a Covaris AFA. The fragmented genomic DNA was end repaired, A-tailed, and ligated to sequencing adaptors, with a purification step between each process. The purified ligated products were then amplified by PCR to generate whole-genome libraries.

In-Solution Hybridization capture with DNA baits {#S14}
------------------------------------------------

Liquid exome capture was performed as previously described^[@R6]^.

Consensus sequence generation and variant calling {#S15}
-------------------------------------------------

Variant calling was performed as previously described^[@R6]^. Briefly, reads obtained from the Illumina Genome Analyzer were post-processed and quality filtered using GERALD, mapped to the genome using BWA, downsampled using Picard, and used to generate a consensus sequence for each sample using GATK. The consensus sequences were then compared to find candidate novel mutations in hiPSCs^[@R6]^. Sites where each hiPSC line showed heterozygous SNPs not observed in the progenitor line were considered as candidate mutations if no allelic content was present in the somatic progenitor and if the candidate mutation had not previously been observed in other samples or the dbSNP database.

Sanger validation of candidate mutations {#S16}
----------------------------------------

Genomic DNA of both the hiPSC line and its somatic progenitor (6 ng each) was amplified in separate 50 μl PCR reactions with 100 nM of specifically designed forward and reverse primers around the mutation site (primers available under request) and 25 μl of Taq 2x master mix (NEB) at 94 °C for 2 minutes, followed by 35 cycles of 94 °C for 30 seconds; 57 °C for 30 seconds; and 72 °C for 30 seconds, and final extension at 72 °C for 3 minutes. The PCR products were then purified with Qiagen Qiaquick columns, and 10 ng of purified DNA was pre-mixed with 25 pmol of the forward primer for Sanger sequencing at Genewiz Inc.

Statistical Analysis/TiGER Database {#S17}
-----------------------------------

To check for enrichment of reprogramming-associated mutations in genes that are expressed in a tissue-specific manner, the fraction of UniGene IDs corresponding to mutated genes called as "tissue-specific" in the TiGER database was identified as 49/132 (37%). As 6,699/19,526 (34%) of the genes annotated in the TiGER database are considered to be tissue-specific, a χ^2^ test with one degree of freedom can be used to test for equivalency of distribution. The obtained χ^2^ value is 0.460, indicating that the fraction of mutated hiPSC genes that are tissue-specific is not significantly different than that found in a random sample of genes (P-value = 0.4975). Reprogramming-associated mutations therefore do not appear to be enriched in tissue-specific genes.

Statistical Analysis/Active and Inactive Chromatin States {#S18}
---------------------------------------------------------

To check for enrichment of reprogramming-associated mutations in active or inactive chromatin, we utilized a χ2 test with three degrees of freedom to test for equivalency of distribution. We identified the chromatin state of each mutated gene using previously published data^[@R13]^. This data divided each gene into one of four categories: no trimethylation, H3K4 Trimethylation, H3K27 Trimethylation, or both. We compared the distribution of mutated genes across each of these four categories with the expected distribution for all genes in three cell types: Fibroblasts, ESCs, and iPSCs^[@R13]^. The obtained χ2 values were 1.03 (p-value=0.79), 3.78 (p-value=0.29), and 6.97 (p-value=0.07), respectively, indicating that the distribution of mutated hiPSC genes in each chromatin region is not significantly different than expected by random chance (alpha=0.01). Reprogramming-associated mutations therefore do not appear to be enriched in active or inactive chromatin states.

Non-coding versus Coding mutations {#S19}
----------------------------------

To compare the mutation rates per base pair in coding and non-coding regions of the genome, variant calling was performed as above on non-coding regions of the genome surviving library enrichment in eight hiPSC lines and their progenitor lines. The mutation rate per base pair was then estimated by dividing the number of candidate coding and non-coding mutations by the number of exomic and non-coding base pairs covered. The average coding and non-coding mutation rates were compared.

Supplementary Material {#S20}
======================
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![Mutated alleles are expressed in hiPSC lines\
Sanger chromatograms showing the results of RNA Sequencing analysis performed on the indicated genes found mutated in the indicated hiPSC lines. Dashed lines highlight the point-mutated nucleotide. Note the expression of both reference and mutated alleles in all cases analyzed.](nihms429070f1){#F1}

![Evaluation of the functional effect of hiPSC mutations on reprogramming efficiency\
(**a, b**) Human BJ fibroblasts were infected with retroviruses encoding OSKC, and either lentiviruses encoding shRNAs against the indicated proteins (**a**) or retroviruses encoding the wild type or mutated proteins (**b**). Relative reprogramming efficiencies (evaluated as percentage of Nanog^+^ colonies) are shown as fold change normalized to the averaged efficiency observed in pLVTHM (**a**) or pMX-GFP (**b**) infected fibroblasts. In (**a**) lentiviruses encoding shRNAs against *CycE1* or *p53* were used as controls of reduced or increased reprogramming efficiency, respectively. In (**b**) retroviruses encoding *p16* or the pair CDK4/CycD1 were used as controls of reduced or increased reprogramming efficiency, respectively. For (**a**), 20,000 infected cells were plated when shRNAs against *POLR1C* and *p53* were used and 70,000 infected cells were plated under all other conditions. For (**b**), a total of 25,000 infected cells were plated under all conditions. Two independent experiments with two biological replicates were carried out. All error bars depict the standard deviation.](nihms429070f2){#F2}

![Retroviral silencing or wild-type/mutant gene ratio do not alter reprogramming efficiency\
(**a**) HUVEC cells were infected with retroviruses encoding OSKC, and a similar total amount of retroviruses encoding only the wild type form or both, the wild-type (wt) and mutant (mut) forms of the protein in an equal proportion. (**b**) HUVEC cells were infected with retroviruses encoding OSKC, red fluorescence protein (RFP) and the wild type or mutated forms of the genes indicated. Relative reprogramming efficiencies (evaluated as percentage of Tra-1-60^+^ colonies) are shown as fold change normalized to the averaged efficiency observed in GFP-infected HUVECs. 10,000 infected cells were plated under all the conditions. Two independent experiments with two biological replicates were carried out. All error bars depict the standard deviation.](nihms429070f3){#F3}

###### 

List of protein-coding mutations in hiPSC lines

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Sample       Chrom.   Position    Gene         Alleles         Protein Change   Mutation Type   SIFT Functional Prediction   Mutated in Cancer?
  ------------ -------- ----------- ------------ --------------- ---------------- --------------- ---------------------------- --------------------
  ASThiPS4F4   6        31783527    LY6G6F       GAC-GAt         D122D            Synonymous      N/A                          Yes

  ASThiPS4F4   8        68087821    LRRC67       CTT-aTT         L121I            Nonsynonymous   TOLERATED                    No

  ASThiPS4F5   11       54891946    OR4A15       CTG-CcG         L4P              Nonsynonymous   DAMAGING                     No

  ASThiPS4F5   13       110343392   ANKRD10      AAG-AAt         K225N            Nonsynonymous   TOLERATED                    Yes

  KhiPS4F8     1        205153901   FAIM3        TTC-aTC         F67I             Nonsynonymous   DAMAGING                     Yes

  KhiPS4F8     5        121215932   FTMT         CAC-CAt         H125H            Synonymous      N/A                          Yes

  KhiPS4F8     14       62486817    KCNH5        GAC-aAC         D386N            Nonsynonymous   TOLERATED                    No

  NSChiPS2F    5        79774746    ZFYVE16      TCT-TaT         S823Y            Nonsynonymous   DAMAGING                     No

  NSChiPS2F    12       54853783    SMARCC2      CCA-CCg         P538P            Synonymous      N/A                          Yes

  HUVhiPS4F1   2        169809670   LRP2         TCG-TtG         S1070L           Nonsynonymous   TOLERATED                    Yes

  HUVhiPS4F1   10       33542444    NRP1         GGC-GaC         G497D            Nonsynonymous   DAMAGING                     No

  HUVhiPS4F1   16       17139792    XYLT1        AAG-AgG         K562R            Nonsynonymous   TOLERATED                    No

  HUVhiPS4F1   4        155376303   DCHS2        GGA-GtA         G2529V           Nonsynonymous   DAMAGING                     No

  HUVhiPS4F3   6        155183150   RBM16        GTA-cTA         V595L            Nonsynonymous   TOLERATED                    No

  HUVhiPS4F3   9        394921      DOCK8        TCA-aCA         S1012T           Nonsynonymous   TOLERATED                    Yes

  HUVhiPS4F3   X        109889590   CHRDL1       CTT-aTT         L86I             Nonsynonymous   TOLERATED                    No

  HUVhiPS4F3   19       7475243     C19orf45     TCA-TaA         S229\*           Nonsense        N/A                          Yes

  MSChiPS4F4   1        35998698    CLSPN        GTG-tTG         V471L            Nonsynonymous   TOLERATED                    Yes

  MSChiPS4F4   1        153185686   PBXIP1       GAC-GgC         D363G            Nonsynonymous   TOLERATED                    Yes

  MSChiPS4F4   2        154960801   GALNT13      GAA-GAg         E403E            Synonymous      N/A                          Yes

  MSChiPS4F4   5        126704124   MEGF10       GTC-GTg         V74V             Synonymous      N/A                          Yes

  MSChiPS4F4   6        130572400   SAMD3        ATG-tTG         M106L            Nonsynonymous   DAMAGING                     Yes

  MSChiPS4F4   10       42974297    CSGALNACT2   ATG-gTG         M264V            Nonsynonymous   TOLERATED                    Yes

  MSChiPS4F4   11       36473107    TRAF6        GAA-aAA         E225K            Nonsynonymous   DAMAGING                     Yes

  MSChiPS4F4   17       50475673    STXBP4       GTA-GTg         V236V            Synonymous      N/A                          Yes

  MSChiPS4F4   19       40938581    HSPB6        TCGCCG-TCatCG   S84S\            Synonymous\     N/A\                         No
                                                                 P85S             Nonsynonymous   DAMAGING                     

  MSChiPS4F4   20       46706999    PREX1        GCC-GCt         A703A            Synonymous      N/A                          Yes

  MSChiPS4F4   21       39493296    BRWD1        AAA-AtA         K1639I           Nonsynonymous   DAMAGING                     Yes

  MSChiPS4F4   X        11688927    MSL3         TCT-TtT         S111F            Nonsynonymous   DAMAGING                     Yes

  MSChiPS4F8   1        39703363    MACF1        GGC-tGC         G5698C           Nonsynonymous   DAMAGING                     Yes

  MSChiPS4F8   1        158594563   NCSTN        TTG-cTG         L670L            Synonymous      N/A                          No

  MSChiPS4F8   1        231873806   KCNK1        GAC-GAt         D224D            Synonymous      N/A                          Yes

  MSChiPS4F8   2        21087987    APOB         CAC-CgC         H1753R           Nonsynonymous   DAMAGING                     Yes

  MSChiPS4F8   2        234287122   UGT1A8       GTC-GaC         V249D            Nonsynonymous   N/A                          Yes

  MSChiPS4F8   5        128390915   SLC27A6      GAC-GAa         D482E            Nonsynonymous   DAMAGING                     No

  MSChiPS4F8   8        16079769    MSR1         CCG-tCG         P34S             Nonsynonymous   TOLERATED                    Yes

  MSChiPS4F8   9        125834763   LHX2         GAG-tAG         E393\*           Nonsynonymous   N/A                          No

  MSChiPS4F8   14       46496570    MDGA2        TTG-aTG         L318M            Nonsynonymous   TOLERATED                    Yes

  MSChiPS4F8   15       37669438    THBS1        TGC-TGt         C689C            Synonymous      N/A                          Yes

  MSChiPS4F8   X        152498688   ATP2B3       TCC-TaC         S1134Y           Nonsynonymous   DAMAGING                     Yes
  -------------------------------------------------------------------------------------------------------------------------------------------------

###### 

List of candidate non-coding mutations in hiPSC lines. The mutation rate per base pair was similar for exonic and non-exonic regions.

  Cell Line     Noncoding Mutations   Exon Mutation Rate (per bp)   Non-exon Mutation Rate (per bp)             
  ------------- --------------------- ----------------------------- --------------------------------- --------- ---------
  ASThiPS4F4    9                     111225067                     C -\> T                           8.0E-08   6.2E-08
  11            64089233              G -\> T                                                                   
  13            38444609              C -\> T                                                                   
                                                                                                                
  ASThiPS4F5    2                     114429763                     A -\> T                           8.0E-08   1.0E-07
  12            55133583              G -\> T                                                                   
  16            2290223               G -\> T                                                                   
  17            40078501              C -\> T                                                                   
                                                                                                                
  FiPS3F1       5                     149190453                     C -\> A                           1.6E-07   1.6E-07
  9             5175241               C -\> T                                                                   
  10            45274877              G -\> T                                                                   
  11            85134161              T -\> C                                                                   
  19            48465587              C -\> A                                                                   
                                                                                                                
  FiPS4F7       1                     171784008                     C -\> A                           1.2E-07   1.3E-07
  2             116251932             C -\> A                                                                   
  2             189575154             C -\> A                                                                   
  9             98839743              G -\> A                                                                   
                                                                                                                
  HUVhiPS4F1    11                    17069813                      G -\> A                           1.6E-07   7.2E-08
  19            21056778              G -\> A                                                                   
                                                                                                                
  HUVhiPS4F3    2                     102515666                     G -\> T                           1.6E-07   1.1E-07
  11            12908191              G -\> T                                                                   
  15            25902050              G -\> A                                                                   
  22            18130926              C -\> T                                                                   
                                                                                                                
  KhiPS4F8      5                     96143123                      C -\> T                           1.2E-07   1.8E-07
  9             122778753             A -\> T                                                                   
  10            85962168              C -\> G                                                                   
  17            71457091              T -\> C                                                                   
                                                                                                                
  NSChiPS2F     5                     110120401                     G -\> T                           8.0E-08   1.2E-07
  9             115077723             C -\> T                                                                   
  9             127398270             C -\> T                                                                   
  11            9457743               T -\> A                                                                   
  19            46045755              T -\> G                                                                   
                                                                                                                
  MSChiPS4F4    1                     6092988                       C -\> G                           4.8E-07   4.2E-07
  2             88885962              C -\> T                                                                   
  2             230820856             T -\> C                                                                   
  3             51088015              G -\> T                                                                   
  4             67994660              T -\> A                                                                   
  4             156930655             C -\> A                                                                   
  5             156683693             G -\> C                                                                   
  6             73887041              C -\> T                                                                   
  6             129865735             A -\> G                                                                   
  8             24379410              T -\> A                                                                   
  10            94807938              T -\> C                                                                   
  10            100179495             G -\> A                                                                   
  14            104534424             G -\> A                                                                   
  15            61826051              G -\> A                                                                   
  18            9551942               C -\> T                                                                   
  X             70543403              T -\> C                                                                   
  X             152791107             A -\> T                                                                   
                                                                                                                
  MSChiPS4F8    1                     39703363                      G -\> T                           4.4E-07   6.5E-07
  1             46422702              G -\> C                                                                   
  1             74608556              C -\> A                                                                   
  1             85589993              A -\> G                                                                   
  2             88885962              C -\> T                                                                   
  2             128062632             A -\> T                                                                   
  3             12183849              G -\> A                                                                   
  4             3200574               C -\> T                                                                   
  4             95415046              A -\> G                                                                   
  4             144675426             G -\> T                                                                   
  6             37430075              G -\> T                                                                   
  6             90653308              G -\> T                                                                   
  6             134570140             T -\> C                                                                   
  7             37123316              T -\> C                                                                   
  7             117661660             A -\> C                                                                   
  9             15258029              C -\> G                                                                   
  9             132317600             C -\> G                                                                   
  14            29171707              C -\> A                                                                   
  14            73445929              C -\> G                                                                   
  16            20968574              C -\> T                                                                   
  16            34177914              C -\> T                                                                   
  17            7778980               G -\> A                                                                   
  17            62783815              G -\> A                                                                   
  18            6877390               C -\> T                                                                   
  19            43784039              C -\> A                                                                   
  X             138470822             G -\> A                                                                   
                                                                                                                
  **AVERAGE**                                                                                         1.9E-07   2.0E-07

[^1]: These authors contributed equally to this work.
